TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29438110

Group type: EXPERIMENTAL
Intervention: Online training module followed by a test module
Number of subjects: 463

Group type: COMPARATOR
Intervention: Test module followed by training module (Control)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Overall agreement for intervention
Number of subjects: 463

Group type: COMPARATOR
Intervention: Overall agreement for control
Number of subjects: 463
Study: 28192622

Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 26193861

Group type: EXPERIMENTAL
Intervention: Lotus root
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cucumber
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 23728065

Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/d, titrated during the first week)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 22215943

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with Peg‐α‐2b interferon (1.5 μg/kg per week) plus ribavirin (1000‐1200 mg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Peg‐α‐2b interferon (1.5 μg/kg per week) plus ribavirin (1000‐1200 mg/d) without vitamin D
Number of subjects: 72
Study: 18987881

Group type: EXPERIMENTAL
Intervention: Two-handed tool use with constant joint and switching target-to-movement mapping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-handed tool use with constant target-to-movement mapping
Number of subjects: 0
Study: 16813138

Group type: EXPERIMENTAL
Intervention: Dental floss
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conical interdental brush
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cylindrical interdental brush
Number of subjects: 50
Study: 12627316

Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes screening
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) screening
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) screening
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: NNTS for undiagnosed diabetes in men
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: NNTS for undiagnosed diabetes in women
Number of subjects: 1353
Study: 11114637

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 53
Study: 9021432

Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin
Number of subjects: 0
Study: 8471571

Group type: EXPERIMENTAL
Intervention: Flumazenil (benzodiazepine antagonist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 40
Study: 3437446

Group type: EXPERIMENTAL
Intervention: Acupuncture and nicotine chewing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29420721

Group type: EXPERIMENTAL
Intervention: Single cryoballoon application per vein
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine dual cryoballoon application
Number of subjects: 140
Study: 26923987

Group type: COMPARATOR
Intervention: GDF5
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTH (1‐34) Teriparatide
Number of subjects: 0
Study: 25529979

Group type: EXPERIMENTAL
Intervention: LX4211 (400 mg for 7 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23765420

Group type: EXPERIMENTAL
Intervention: C-seal
Number of subjects: 37
Study: 20514695

Group type: EXPERIMENTAL
Intervention: ECT with hyperventilation
Number of subjects: 25

Group type: COMPARATOR
Intervention: ECT without hyperventilation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 18401199

Group type: EXPERIMENTAL
Intervention: Multiple daily injections with indwelling catheter (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multiple daily injections without indwelling catheter (Group B)
Number of subjects: 40
Study: 20638772

Group type: EXPERIMENTAL
Intervention: Straddling external chest compression
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard external chest compression
Number of subjects: 20
Study: 15791507

Group type: EXPERIMENTAL
Intervention: Maki's semiquantitative technique
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Sonication
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Vortexing
Number of subjects: 1000
Study: 11495387

Group type: EXPERIMENTAL
Intervention: Nursing-led ward care (treatment group)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 177
Study: 9773742

Group type: EXPERIMENTAL
Intervention: Good-to-moderate glycemic control (GHb <= 9%)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Poor glycemic control (GHb >= 9%)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: GHb as a continuous variable
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: GHb as a categorical variable with cutoff level of 9%
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Duration of diabetes, age, and male sex
Number of subjects: 97
Study: 7820976

Group type: EXPERIMENTAL
Intervention: Leucine infusion (1 g h‐1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Glucose infusion (20 g h‐1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of leucine and glucose infusions
Number of subjects: 11
Study: 2970367

Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (NET-EN)
Number of subjects: 18
Study: 30536154

Group type: EXPERIMENTAL
Intervention: ICH glasdegib (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ICH glasdegib (100 mg) after high-fat, high-calorie meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: ICH glasdegib (100 mg) with PPI (rabeprazole)
Number of subjects: 24
Study: 28994677

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine (DK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol-ketamine (PK)
Number of subjects: 60
Study: 26615369

Group type: EXPERIMENTAL
Intervention: Aspirin challenge
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Baseline levels in AERD patients
Number of subjects: 38
Study: 25295770

Group type: EXPERIMENTAL
Intervention: Activity prescription intervention targeting exercise intensity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Activity prescription intervention targeting sedentary intensity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Activity prescription intervention targeting both exercise and sedentary intensity
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 60
Study: 23181957

Group type: EXPERIMENTAL
Intervention: Face-to-face counselling
Number of subjects: 116

Group type: COMPARATOR
Intervention: Written information
Number of subjects: 116
Study: 19390069

Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional Functional Rehabilitation (FR)
Number of subjects: 35
Study: 17722433

Group type: EXPERIMENTAL
Intervention: Tongue scraper used 2-3 times a day
Number of subjects: 10

Group type: COMPARATOR
Intervention: No tongue scraper (control)
Number of subjects: 10
Study: 15500257

Group type: EXPERIMENTAL
Intervention: Comfrey extract ointment (Kytta-Salbe f, four treatments per day for 8 days)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 11584376

Group type: EXPERIMENTAL
Intervention: Lamivudine 25 mg daily
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg 3 times a day before lamivudine 100 mg daily
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: YMDD variants present 3 months before HBV DNA breakthroughs
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA breakthroughs
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: HBV DNA levels > 10(3) copies/mL after 6 months of lamivudine therapy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: HBeAg seroconversion
Number of subjects: 159
Study: 9693949

Group type: EXPERIMENTAL
Intervention: Circular questioning style
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reflexive questioning style
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lineal questioning style
Number of subjects: 120

Group type: COMPARATOR
Intervention: Strategic questioning style
Number of subjects: 120
Study: 7872992

Group type: EXPERIMENTAL
Intervention: Cimetidine treatment for one week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment for one week
Number of subjects: 22
Study: 3279350

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29426379

Group type: EXPERIMENTAL
Intervention: Probable DCD
Number of subjects: 0
Study: 27272937

Group type: EXPERIMENTAL
Intervention: Walking intervention (n=60): instructed to walk briskly for 30 minutes, three times weekly from 30 weeks' gestation until delivery
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (n=58): counted daily steps using pedometers
Number of subjects: 118
Study: 24112810

Group type: EXPERIMENTAL
Intervention: Meal replacement (MR) group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional reduced-fat diet (CD) group
Number of subjects: 46
Study: 22571244

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study: 19844211

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 9
Study: 18029109

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Captopril (for subjects who received the study drug for more than 2 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (for subjects who received the study drug for more than 2 months)
Number of subjects: 55
Study: 15738010

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin (5.1 mg/kg every 24 hours; n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard dosing of gentamicin (120 mg followed by 80 mg every 8 hours; n = 20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard dosing of gentamicin
Number of subjects: 38
Study: 12166534

Group type: EXPERIMENTAL
Intervention: 20 microg/day of vitamin D3
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 50
Study: 10592457

Group type: EXPERIMENTAL
Intervention: Recombinant human GH, 15.5 IU/m(2) body surface per week, subcutaneously, for at least 2 years
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: GH therapy in three dosage groups for girls with Turner's syndrome: Group A (4 IU/m(2)), Group B (4 IU/m(2) first year, 6 IU/m(2) thereafter), Group C (4 IU/m(2) first year, 6 IU/m(2) second year, 8 IU/m(2) thereafter)
Number of subjects: 552
Study: 8521713

Group type: EXPERIMENTAL
Intervention: Methotrexate and misoprostol
Number of subjects: 86
Study: 2253495

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Other antibiotics (netilmicin and tobramycin)
Number of subjects: 30
Study: 337746

Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study: 30451604

Group type: EXPERIMENTAL
Intervention: Psychosocial empowerment program based on the Integrative Body-Mind-Spirit model; delivered in a parallel group format.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group; no intervention provided during the study period.
Number of subjects: 0
Study: 27215298

Group type: EXPERIMENTAL
Intervention: Free sachet water vouchers (15 L/week/child) plus education
Number of subjects: 86

Group type: COMPARATOR
Intervention: Half-price sachet water vouchers (15 L/week/child) plus education
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group received education about diarrhea
Number of subjects: 86
Study: 24006222

Group type: EXPERIMENTAL
Intervention: More than two immunotherapies
Number of subjects: 60

Group type: COMPARATOR
Intervention: Two immunotherapies
Number of subjects: 60
Study: 21752101

Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus Mycophenolate mofetil (3 g/day, 1.5 g twice daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Methylprednisolone alone (1 mg/kg)
Number of subjects: 47
Study: 19925203

Group type: EXPERIMENTAL
Intervention: Music listening group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audio book listening group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 18207164

Group type: EXPERIMENTAL
Intervention: ARV‐VRT
Number of subjects: 10

Group type: COMPARATOR
Intervention: seeing field‐VRT
Number of subjects: 10
Study: 15753541

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12519419

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment (0.04 U/kg/day for 14 weeks preoperatively and doubled for the first 2 weeks postoperatively)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10770449

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 9075195

Group type: EXPERIMENTAL
Intervention: Formula containing palm-olein, high oleic sunflower, coconut and soy oil
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Formula containing coconut and soy oil
Number of subjects: 172

Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: All infant groups
Number of subjects: 172
Study: 8441966

Group type: EXPERIMENTAL
Intervention: Routine intraoperative cholangiography (IOC)
Number of subjects: 280

Group type: COMPARATOR
Intervention: No intraoperative cholangiography (no-IOC)
Number of subjects: 280
Study: 3097099

Group type: EXPERIMENTAL
Intervention: Intravenous administration of recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 29843467

Group type: EXPERIMENTAL
Intervention: New HM fortifier (nHMF; n = 26) containing 12.5 g medium‐chain FA, 958 mg linoleic acid, 417 mg α‐linolenic acid, and 157 mg docosahexaenoic acid per 100 g of powder
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fat-free HMF (cHMF; n = 21)
Number of subjects: 47
Study: 26889350

Group type: EXPERIMENTAL
Intervention: 2.0 mm locking plates
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2.0 mm nonlocking (traditional) plates
Number of subjects: 20
Study: 23821454

Group type: EXPERIMENTAL
Intervention: Any vertebral fracture
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Mild vertebral fractures discounted
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Mild vertebral fractures
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Moderate vertebral fractures
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Severe vertebral fractures
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Cumulative fracture grades 1 to 3
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Cumulative fracture grades 4 to 6
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Cumulative fracture grades ≥7
Number of subjects: 576
Study: 22872363

Group type: EXPERIMENTAL
Intervention: Harmonic Focus Curved Shears
Number of subjects: 19

Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 19
Study: 20307126

Group type: EXPERIMENTAL
Intervention: Brief image‐based prevention intervention
Number of subjects: 416

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 416
Study: 18604681

Group type: EXPERIMENTAL
Intervention: Polyglactin mesh
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Polydioxanone or polyglactin sutures
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no polyglactin mesh)
Number of subjects: 86
Study: 16001680

Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay for p16
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay for E‐cadherin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay for RARbeta
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay overall
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional serum tumor markers (carcinoembryonic antigen or carbohydrate antigen 19‐9)
Number of subjects: 63
Study: 11450476

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9669003

Group type: COMPARATOR
Intervention: Normothermic CPB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB
Number of subjects: 20
Study: 8002119

Group type: EXPERIMENTAL
Intervention: Acute hypoxia at Low Altitude (FIO2 = 0.137 +/‐ 0.001)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acute normoxia at High Altitude (FIO2 = 0.306 +/‐ 0.006)
Number of subjects: 25
Study: 3400296

Group type: EXPERIMENTAL
Intervention: Various therapies for chronic cardiovascular diseases
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Markoff-model application
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Therapy-dependent susceptibility analysis
Number of subjects: 1000
Study: 8396087

Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 252) 500 mg once daily for three days
Number of subjects: 510

Group type: COMPARATOR
Intervention: Clarithromycin (n = 258) 250 mg twice daily for ten days
Number of subjects: 510
Study: 679555

Group type: EXPERIMENTAL
Intervention: Graded-compression antiembolism stockings
Number of subjects: 18

Group type: COMPARATOR
Intervention: No stockings (Control)
Number of subjects: 18
Study: 31710844

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (1 ng/kg/min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 50
Study: 31106548

Group type: EXPERIMENTAL
Intervention: Walking more than 10,000 steps (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Walking 5,000-9,999 steps (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Walking less than 5,000 steps (Group A)
Number of subjects: 90
Study: 28103276

Group type: EXPERIMENTAL
Intervention: Honey type 1 (Kimia Company, Iran)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Honey type 2 (Shahde-Golha, Iran)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Diphenhydramine (DPH)
Number of subjects: 87
Study: 25596108

Group type: EXPERIMENTAL
Intervention: Radiation therapy to the anorectum and rectum
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Radiation therapy to the anal canal
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Radiation therapy to the rectum
Number of subjects: 754
Study: 23656847

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Parenting education program
Number of subjects: 142
Study: 21161263

Group type: EXPERIMENTAL
Intervention: Limb in down position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Limb in horizontal position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Limb in up position
Number of subjects: 20
Study: 20031019

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid bound spermatozoa (HA(+))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-bound spermatozoa (HA(-))
Number of subjects: 44
Study: 17185127

Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: K3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hand Hedstrom files
Number of subjects: 60
Study: 15504839

Group type: EXPERIMENTAL
Intervention: SR clarithromycin (500 mg daily)
Number of subjects: 296
Study: 11241124

Group type: EXPERIMENTAL
Intervention: Heparin-bonded Dacron (HBD)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 209
Study: 9582180

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8116811

Group type: EXPERIMENTAL
Intervention: Halofantrine (3 doses of 500 mg each at 4-hr intervals on the first day, followed by 500 mg a day for six days; total dose 4.5 g)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Quinine-tetracycline (Q7T7 for seven days)
Number of subjects: 26
Study: 3396574

Group type: EXPERIMENTAL
Intervention: Fasted for 36 h (A)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Postabsorptive (overnight fast, D)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fasted (36 h) and refed with glucose (B)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fasted (36 h) and refed with glycerol (C)
Number of subjects: 5
Study: 31446787

Group type: EXPERIMENTAL
Intervention: Normal cardiac function
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Stage A heart failure
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Stage B heart failure
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Stage C heart failure
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Stage D heart failure
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Elevated body mass index (BMI)
Number of subjects: 535
Study: 30305115

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 89